

BANQUE CARNEGIE LUXEMBOURGH S A

Form SC 13G/A

February 14, 2007

OMB APPROVAL  
OMB Number: 3235-0145  
Expires: February 28, 2009  
Estimated average burden  
hours per response...10.4

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**Under the Securities Exchange Act of 1934  
(Amendment No. One)\***

Infinity Pharmaceuticals, Inc. (f/k/a Discovery Partners, International, Inc.)  
(Name of Issuer)  
Common Stock  
(Title of Class of Securities)  
2546751015  
(CUSIP Number)  
December 31, 2006  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 2546751015

Page 2 of 9

NAMES OF REPORTING PERSONS:

1

Banque Carnegie Luxembourg S.A.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b)

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

Luxembourg

SOLE VOTING POWER:

5

NUMBER OF

SHARES  
BENEFICIALLY  
OWNED BY

6

SHARED VOTING POWER:

0

EACH  
REPORTING  
PERSON

7

SOLE DISPOSITIVE POWER:

WITH:

8

SHARED DISPOSITIVE POWER:

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

0

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

0%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

HC/BK

---

NAMES OF REPORTING PERSONS:

1 Carnegie Fund Management Company S.A.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2  
(a)   
(b)

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4  
Luxembourg

SOLE VOTING POWER:

5

NUMBER OF

SHARES  
BENEFICIALLY OWNED BY  
6

SHARED VOTING POWER:

0

EACH  
REPORTING PERSON  
7

SOLE DISPOSITIVE POWER:

WITH:  
8

SHARED DISPOSITIVE POWER:

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9  
0

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

0%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

IV

---

NAMES OF REPORTING PERSONS:

1

Carnegie Investment Bank AB

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b)

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

Denmark

SOLE VOTING POWER:

5

NUMBER OF

SHARES  
BENEFICIALLY  
OWNED BY

6

SHARED VOTING POWER:

0

EACH  
REPORTING  
PERSON

7

SOLE DISPOSITIVE POWER:

WITH:

8

SHARED DISPOSITIVE POWER:

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

0

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

0%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

HC/BK/IA

---



NAMES OF REPORTING PERSONS:

1

D Carnegie & Co. AB

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b)

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

Sweden

SOLE VOTING POWER:

5

NUMBER OF

SHARES  
BENEFICIALLY  
OWNED BY

6

SHARED VOTING POWER:

0

EACH  
REPORTING  
PERSON

7

SOLE DISPOSITIVE POWER:

WITH:

8

SHARED DISPOSITIVE POWER:

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

0

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

0%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

HC

---

**Item 1(a). Name of Issuer**

The name of the issuer is Infinity Pharmaceuticals, Inc. (f/k/a Discovery Partners, International, Inc.).

**Item 1(b). Address of Issuer's Principal Executive Offices**

The address of the issuer's principal executive offices is 780 Memorial Drive, Cambridge, MA 02139.

**Item 2(a). Name of Person Filing**

Banque Carnegie Luxembourg S.A.  
Carnegie Fund Management Company S.A.  
Carnegie Investment Bank AB  
D Carnegie & Co. AB

**Item 2(b). Address of Principal Business Office or, if None, Residence**

Banque Carnegie Luxembourg S.A.  
Carnegie Fund Management Company S.A.  
Centre Europe  
5, Place de la Gare  
L-1616 Luxembourg  
Grand-Duchy of Luxembourg  
D Carnegie & Co AB  
Carnegie Investment Bank AB  
Vastra Tradgardsgatan 15  
SE-103 38, Stockholm  
Sweden

**Item 2(c). Citizenship**

Banque Carnegie Luxembourg S.A. Luxembourg  
Carnegie Fund Management Company S.A. Luxembourg  
Carnegie Investment Bank AB Denmark  
D Carnegie & Co. AB Sweden  
Carnegie Investment Bank AB Sweden

**Item 2(d). Title of Class of Securities**

Common Stock

**Item 2(e). CUSIP Number**

2546751015

**Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:**

See cover pages, Item 12.

**Item 4. Ownership**

(a) Amount beneficially owned by the group: 0.

(b) Percent of class: 0%

(c) Number of shares to which the person has:

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 0

**Item 5. Ownership of Five Percent or Less of a Class**

This statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities [X].

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which acquired the Security Being Reported on by the Parent Holding Company**

Carnegie Fund Management Company S.A. is a wholly owned subsidiary of Banque Carnegie Luxembourg S.A. Banque Carnegie Luxembourg S.A. is a wholly owned subsidiary of Carnegie Investment Bank AB, which in turn is a wholly owned subsidiary of D Carnegie & Co. AB. Carnegie Investment Bank AB is the Investment Manager for Carnegie Fund Management Company S.A.

**Item 8. Identification and Classification of Members of the Group**

Carnegie Fund Management Company S.A. is a wholly owned subsidiary of Banque Carnegie Luxembourg S.A. Banque Carnegie Luxembourg S.A. is a wholly owned subsidiary of Carnegie Investment Bank AB, which in turn is a wholly owned subsidiary of D Carnegie & Co. AB. Carnegie Investment Bank AB is the Investment Manager for Carnegie Fund Management Company S.A.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 8 of 9

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2007

Banque Carnegie Luxembourg S.A.(1)

/s/ W. T. Eggleston, Jr.

Name: W. T. Eggleston, Jr.

Title: Attorney-in-Fact

(1) Pursuant to a Joint Filing Agreement among Carnegie Fund Management Company S.A., Banque Carnegie Luxembourg S.A., Carnegie Investment Bank AB, and D Carnegie & Co. AB, this Schedule 13G is filed on behalf of each of them.

Page 9 of 9